Trials in Chicago, Illinois
Here are the top 10 medical studies for lung cancer in Chicago, Illinois
Popular Filters
Phase 3 Trials
PD-1 Inhibitor
Pembrolizumab + Olaparib/Pemetrexed for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is comparing two treatment combinations for a specific type of lung cancer. It aims to find out which combination helps patients live longer and keeps their cancer from getting worse. The treatments work by boosting the immune system, making it harder for cancer cells to repair themselves, or stopping their growth.
Romiplostim for Chemotherapy-Induced Low Platelet Count
Recruiting1 awardPhase 3
Chicago, Illinois
This trial tests romiplostim, a drug that boosts platelet production, in adults with certain cancers undergoing chemotherapy. It aims to help these patients maintain their chemotherapy schedule by increasing their platelet counts. Romiplostim has shown effectiveness in increasing platelet counts in patients with low platelet levels due to chemotherapy.
Alkylating agents
Pembrolizumab + Chemotherapy for Lung Cancer
Recruiting2 awardsPhase 3
Jonesboro, Arkansas
This trial is studying whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with advanced non-squamous non-small cell lung cancer.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Jonesboro, Arkansas
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Jonesboro, Arkansas
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Radiation Therapy
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Brain Metastasis from Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus for the treatment of small cell lung cancer that has spread to the brain.
Trials With No Placebo
PD-1 Inhibitor
Pembrolizumab + Olaparib/Pemetrexed for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Chicago, Illinois
This trial is comparing two treatment combinations for a specific type of lung cancer. It aims to find out which combination helps patients live longer and keeps their cancer from getting worse. The treatments work by boosting the immune system, making it harder for cancer cells to repair themselves, or stopping their growth.
Alkylating agents
Pembrolizumab + Chemotherapy for Lung Cancer
Recruiting2 awardsPhase 3
Jonesboro, Arkansas
This trial is studying whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with advanced non-squamous non-small cell lung cancer.
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
Monoclonal Antibodies
Amivantamab for Lung Cancer
Recruiting1 awardPhase 1
Chicago, Illinois
This trial is testing a new drug called Amivantamab alone and with other treatments in patients with advanced lung cancer that hasn't responded to other treatments. The goal is to see if these combinations are safe and effective. The drugs work by stopping cancer cells from growing. Amivantamab targets a rare lung cancer mutation that has been difficult to treat with existing medications.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Jonesboro, Arkansas
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.